RE:RE:RE:RE:RE:RE:do you thinkWhat kind of deals, digitel? And what would potential deal makers require before they would do a deal?
I remember back in the day when speculation was rife about Resverlogix (T.RVX) doing a deal. The question always arose about whether RVX could do a deal while it was in clinical trials. Why would a potential partner or buyer enter a deal when the company was engaged in activities that could derisk the investment.
Reducing risk is paramount to those who make decisions at pharmaceutical companies. These people are employees engaged in entrepreneurial activities. If a deal turns out great then they're heros. If it turns out bad then questions are asked about the due diligence that these employees did to inform their decision. When a major derisking effort is underway at the targeted company, would these employees risk their careers by buying a company that has almost, but not quite, finished those studies?
Bioasis is doing such studies. It's been posted on here that if a suite of NHP and other studies are successfully completed then those studies, all of them combined, could prove to be over 90% correctly predictive of similar human clinical trial results.
So, could anybody be watching? Waiting? Interested? Excited?
They're human. They oughtta be excited. Not saying that they are interested and excited but treating brain tumors and all those other diseases is no small thing.
Might be a wise thing, digitel, to think this out just a little bit better.
jdstox